New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSermorelin vs PNC-27

Sermorelin vs PNC-27

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone PeptidesAnti-Aging & Longevity
Sermorelin
Immune Support
PNC-27
Summary
Sermorelin is a bioidentical synthetic peptide comprising the first 29 amino acids of naturally occurring GHRH. It is FDA-approved for diagnostic use and widely prescribed off-label for anti-aging, stimulating growth hormone production in a natural pulsatile pattern that mimics the body's own rhythm.
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
Half-Life
10–20 minutes
Not well established; estimated minutes to hours
Admin Route
SubQ
Intravenous (research), Intraperitoneal (research)
Research
Typical Dose
200–500 mcg
Not established for humans; research doses vary by cell line and model
Frequency
5–7 days per week
Not established for human use
Key Benefits
  • Increases energy and vitality
  • Improves body composition (more muscle, less fat)
  • Enhances skin thickness and elasticity
  • Strengthens immune system
  • Improves sleep quality and REM sleep
  • Supports bone density
  • Enhances mental clarity and focus
  • Safer than exogenous HGH — respects natural feedback loops
  • FDA-approved for GH diagnostic use
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
Side Effects
  • Injection site irritation
  • Flushing
  • Headache
  • Dizziness
  • +2 more
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
Stacks With